Older patients with advanced HER2+ breast cancer do not experience a survival benefit with trastuzumab emtansine vs standard-of-care combination therapy, although toxicity is improved, a trial shows.
'In the countries where ibrutinib is indicated, this combination should be a new standard therapy for relapsed/refractory mantle cell lymphoma.'
Merck said on Friday a combination therapy being developed with partner Eisai failed a late-stage trial testing it as a first-line treatment for a type of cancer in the uterus lining.
Bullous pemphigoid has high morbidity and mortality, especially in people with comorbidities common to older adults, yet no Food and Drug Administration–approved therapies for BP exist.
A new trial from Italy challenges a decades-old assumption that autologous stem cell transplant is more effective than radioimmunotherapy for consolidation after follicular lymphoma relapse.